S&P 500 index data: S&P 500 Copyright ©
All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright Morningstar, Inc .
|Start Premium Trial||Register For Free|
|P||F||Fund Financial Data (13,000+ funds)|
|P||F||Stock Financial Data (7,000+ stocks)|
|P||F||Stock and Fund Screeners (basic)|
|P||F||Investing Articles and Market Commentary|
|P||F||Articles Archive (>30 days)|
|P||F||Discuss (dozens of stock, fund, bond, and general bulletin boards)|
|P||F||Portfolio Manager (basic)|
|P||F||Morningstar Investment Classroom|
|P||F||Access Your Portfolio Anytime, Anywhere via Your Mobile Device|
|P||Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)|
|P||Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)|
|P||Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)|
|P||Portfolio Monitor (monthly and on-demand personalized portfolio statements)|
|P||Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)|
|P||Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters|
|P||Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)|
|P||Discounts on Morningstar newsletters, books, seminars, and more|
Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.
Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.
|Regeneron and Sanofi's Cholesterol Drug Succeeds in Late-Stage Study (2013/10/16)|
|Sanofi, Regeneron Report Positive Results With Sarilumab Phase 3 Trial (2013/11/22)|
|UPDATE: GT Advanced Technologies surges on Apple deal (2013/11/5)|
|Regeneron Announces Appointment of Robert E. Landry as Senior Vice President, Finance and Chief Financial Officer (2013/9/10)|
|Regeneron and Bayer Report Positive One-Year Results from Two Phase 3 Trials of EYLEA® (aflibercept) Injection for the Treatment of Diabetic Macular Edema ()|
|EYLEA® (aflibercept) Injection Submitted for EU Marketing Authorization for the Treatment of Diabetic Macular Edema (2013/11/7)|
|EYLEA® (aflibercept) Injection Approved For The Treatment of Macular Edema Following Central Retinal Vein Occlusion In Japan (2013/11/22)|
|Regeneron to Present Phase 3 Data for EYLEA® (aflibercept) Injection in Diabetic Macular Edema at Upcoming Retina Society Meeting (2013/9/17)|
|Regeneron Highlights EYLEA® (aflibercept) Injection Data to Be Presented at American Academy of Ophthalmology Annual Meeting (2013/11/12)|
|Regeneron Named Top Employer in the Global Biopharmaceutical Industry for the Second Year in a Row (2013/10/24)|
Click above to view more mutual fund data and stats for regn - Regeneron Pharmaceuticals, Inc..